Xencor Inc. Files 8-K on Financials and Operations

Ticker: XNCR · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1326732

Xencor Inc 8-K Filing Summary
FieldDetail
CompanyXencor Inc (XNCR)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.01, $707 m, $697.0 million
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, operations, sec-filing

Related Tickers: XNCR

TL;DR

XNCR filed an 8-K on Jan 13, 2025, covering financials and operations. Check for updates.

AI Summary

Xencor Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Pasadena, California.

Why It Matters

This 8-K filing provides crucial updates on Xencor's financial health and operational status, which are important for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial and operational information, not indicating any immediate adverse events.

Key Numbers

  • 001-36182 — SEC File Number (Identifies the company's filing with the SEC.)
  • 20-1622502 — IRS Employer Identification Number (Company's tax identification number.)

Key Players & Entities

  • Xencor Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • Pasadena, California (location) — Principal Executive Offices

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it covers 'Results of Operations and Financial Condition' but does not detail specific figures within the provided text.

Are there any new material events disclosed under Regulation FD?

The filing states it includes 'Regulation FD Disclosure,' but the specific disclosures are not detailed in the provided text.

What types of exhibits are included with this 8-K filing?

The filing mentions 'Financial Statements and Exhibits,' but the specific nature of these exhibits is not detailed in the provided text.

When was Xencor Inc. incorporated?

Xencor Inc. was incorporated in Delaware.

What is the primary business address of Xencor Inc.?

The primary business address is 465 North Halstead Street, Suite 200, Pasadena, California 91107.

Filing Stats: 817 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2025-01-13 08:08:29

Key Financial Figures

  • $0.01 — ich Registered Common Stock, par value $0.01 per share XNCR Nasdaq Global Market I
  • $707 m — of December 31, 2024 were approximately $707 million, compared to $697.0 million as of
  • $697.0 million — approximately $707 million, compared to $697.0 million as of December 31, 2023. Based on curre

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. Xencor, Inc. (the "Company") preliminarily estimates that its cash, cash equivalents and marketable debt securities as of December 31, 2024 were approximately $707 million, compared to $697.0 million as of December 31, 2023. Based on current operating plans, Xencor expects to have cash to fund research and development programs and operations into 2028. These preliminary estimates are not a comprehensive statement of the Company's financial results for the year ended December 31, 2024 and have not been audited, reviewed, or compiled by its independent registered public accounting firm. The Company's actual cash, cash equivalents and marketable debt securities as of December 31, 2024 may differ from these estimates due to the completion of the Company's year-end closing and auditing procedures. The information furnished under this Item 2.02 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 13, 2025, the Company posted a presentation on the "Investors" section of the Company's website (www.xencor.com), which includes (i) a preliminary estimate for cash, cash equivalents and marketable debt securities as of December 31, 2024 (unaudited); (ii) new preclinical data demonstrating the selectivity of XmAb541 (CLDN6 x CD3) for binding to CLDN6 over CLDN9; (iii) data demonstrating deep peripheral B-cell depletion observed with plamotamab (CD20 x CD3) in a Phase 1 study in patients with lymphoma; (iv) the status of XmAb808 (B7-H3 x CD28) as having resumed dose escalation; and (v) completion of enrollment in the three ongoing studies of vudalimab (PD-1 x CTLA-4). The information contained in, or that can be accessed through, the Company's website is not a part of this filing. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The presentation is current as of January 13, 2025 and the Company disclaims any obligation to update this material. The information furnished under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Presentation dated January 13, 2025. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2025 XENCOR, INC. By: /s/ Celia Eckert Celia Eckert General Counsel & Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.